Polymer-encapsulated engineered adult mesenchymal stem cells secrete exogenously regulated rhBMP-2, and induce osteogenic and angiogenic tissue formation

Polymers for Advanced Technologies

Volumn 13, Issue 10-12, 2002, Pages 863-870

  Zilberman, Yoram ^a   Turgeman, Gadi ^a   Pelled, Gadi ^a   Xu, Nong ^b,c   Moutsatsos, Ioannis K ^d   Hortelano, Gonzalo ^b,c   Gazit, Dan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MCMASTER UNIVERSITY   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d PFIZER INC   (United States)

Author keywords

Alginate; Bone formation; Fracture healing; Gene theraphy; Mesenchymal stem cell; Micro encapsulation; RhBMP 2

Indexed keywords

BONE; CELLS; GENETIC ENGINEERING; IMMUNOLOGY; PROTEINS;

ADULT MESENCHYMAL STEM CELLS (AMSCS);

ORGANIC POLYMERS;

BIOTECHNOLOGY; GENETIC MODIFICATION;

EID: 0036825851     PISSN: 10427147     EISSN: None     Source Type: Journal    
DOI: 10.1002/pat.231     Document Type: Article

References (32)

1. Chaudhari A, Ron E, Rethman MP. Recombinant human bone morphogenetic protein-2 stimulate differentiation in primary cultures of fetal rat calvarial osteoblasts. Mol. Cell. Biochem. 1997; 167: 31-39.
2. Yamaguchi AT, Ishizuya N, Kintou Y, Wada T, Ketagiri J, Wozney M, Rosen V, Yoshiki S. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem. Biophysiol. Res. Comm. 1996; 220: 366-371.
3. Volek-Smith H, Urist MR. Recombinant human bone morphogenetic protein (rhBMP) induce heterotopic bone development in vivo and in vitro. PSEBM 1996; 211: 265-272.
4. Hanada KJE, Dennis AJ, Caplan AI. Stimulatory effects of basic fibroblast growth factor and bone morphogenetic protein-2 on osteogenic differentiation of rat bone marrow derived mesenchymal stem cells. J. Bone Miner. Res. 1997; 12: 1606-1614.
5. Lacenda F, Avioly LV, Cheng SL. Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cells by bone morphogenetic protein-2. J. cell Biochem. 1997; 67: 386-396.
6. Fromigue O, Marie PJ, Lomri A. Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation. J. cell Biochem. 1998; 68: 411-426.
7. Gori F, Thomas T, Hicok CK, Spelberg TC, Riggs BL. Differentiation of human marrow stromal cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment and inhibits late adipocyte maturation. J. Bone Miner. Res. 1999; 14: 1522-1534.
8. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kritz RW, Hewick RM, Wang EA. Novel regulation of bone formation: molecular clones and activities. Science 1998; 242: 1528-1534.
9. Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G, Tzur L, Kelley P, Stumm N, Mi S, Müller R, Zilberman Y, and Gazit D. Exogenously regulated stem cell mediated gene therapy for bone regeneration. Mol. Ther. 2001; 3: 449-461.
10. Baltzer AW, Lattermann C, Whalen JD, Wooly P, Weiss K, Grimm M, Ghivizzani SC, Robbins PD, Evans CH. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther. 2000; 7: 734-739.
11. Lieberman JR, Le LQ, Wu L, Finerman GAM, Berk A, Witte ON, Stevenson S. Regional gene therapy with a BMP-2 producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J. Orthop. Res. 1998; 16: 330-339.
12. Lieberman JR, Daluiski A, Stevenson LA, Jolla L, Wu L, McAllister P, Lee YP, Kabo JM, Finerman GAM, Berk AJ, Witte ON. The effect of regional gene therapy with bone morphogenetic protein-2 producing bone marrow cells on the repair of segmental defects in rats. J. Bone and Joint Surg. 1999; 81: 905-917.
13. Gazit D, Turgeman G, Kelly P, Zilberman Y, Moutsatsos I. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J. Gene Med. 1999; 1(2): 121-133.
14. Turgeman G, Pittman D, Müller R, Kurkalli BG, Zhou S, Pelled G, Peyser A, Zilberman Y, Gazit D. Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy. J. Gene Med. 2001; 3: 240-251.
15. Chang PL, Van Raamsdonk JM, Hortelano G, Barsoum SC, MacDonald NC, Stockley TL. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotech. 1999; 17: 78-83.
16. Chang PL, Hortelano G, Tse M, Awrey DE. Growth of recombinant fibroblasts in alginate microcapsules. Biotechnol. Bioeng. 1994; 43: 925-933.
17. Tse M, Uludag H, Sefton MV, Chang PL. Secretion of recombinant proteins from hydroxyethyl methacrylate-methyl methacrylate capsules. Biotechnol. Bioeng. 1996; 51: 271-280.
18. O'Shea G, Goosen M, Sun A. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim. Biophys. Acta 1984; 804: 133-136.
19. Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp. Neurol. 1993; 122: 100-106.
20. Stevenson WT, Evangelista RA, Sugamori ME, Sefton MV. Microencapsulation of mammalian cells in a hydroxyethyl methacrylate-methyl methacrylate copolymer: preliminary development. Biomater. Artif. Cells Artif. Organs 1988; 16(4): 747-769.
21. Carmen Bano M, Cohen S, Visscher KB, Allcock HR, Langer R. A novel synthetic method for hybridoma cell encapsulation. Biotechnol. 1991; 9: 468-471.
22. Aomatsu Y, Iwata H, Takagi T, Amemiya H, Nakajima Y, Kanehiro H, Hisanaga M, Fukuoka T, Nakano H. Microencapsulated islets in agarose gel as bioartifical pancreas for discordant xenotransplantation. Transplant. Proc. 1992; 24: 2922-2923.
23. Smidsrod O, Skjak-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol. 1990; 8: 71-78.
24. Sun AM. microencapsulation of pancreatic-islet cells - a bioartificial endocrine pancreas. Methods Enzymol. 1988; 137: 575-579.
25. Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy. Hum. Gene Ther. 1995; 6: 165-175.
26. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 1996; 87: 1-9.
27. Peirone M, Delaney K, Kwiecin J, Fletch A, Chang PL. Delivery of recombinant gene product to canines with nonautologous microencapsulated cells. Hum. Gene Ther. 1998; 9: 195-206.
28. Read TA, Sorensen DR, Mahesparan R, Enger P, Timpl R, Olsen BR, Hjelstuen MHB, Haraldseth O, Bjerkvig R. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotech. 2001; 19: 29-34.
29. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotech. 2001; 19: 35-39.
30. Springer ML, Hortelano G, Wong J, Kraft PE, Blau HM. Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. J. Gene Med. 2000; 2: 279-288.
31. Al-Hendy A, Hortelano G, Tannenbaum GS, Chang PL. Growth retardation an unexpected outcome from growth hormone gene therapy in normal mice with microencapsulated myoblasts. Hum. Gene Ther. 1996; 7: 61-70.
32. Theis RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 1992; 130: 1318-1324.